CENTCHROMAN VERSUS TAMOXIFEN FOR THE MANAGEMENT OF MASTALGIA: A RANDOMISED CONTROLLED TRIAL drsatyaprakash04@gmail.com

 

CENTCHROMAN VERSUS TAMOXIFEN FOR THE MANAGEMENT OF MASTALGIA: A RANDOMISED CONTROLLED TRIAL

2

 

 

 

 

India

Oral or Poster

Mastalgia is a common clinical complaint among women of reproductive age and may significantly affect their quality of life. While Tamoxifen has been widely used for pharmacological management, its side effect profile limits long-term use. Centchroman has emerged as a promising alternative with fewer adverse effects. This randomized controlled trial aimed to compare the efficacy of Centchroman and Tamoxifen.

A total of 68 women with mastalgia were randomly assigned to receive either Centchroman or Tamoxifen for a duration of 12 weeks. VAS scores were recorded at baseline, 4, 8, and 12 weeks (end of treatment) to assess pain relief. Patient satisfaction was evaluated using a 5-point Likert scale. In patients with palpable breast lumps, clinical assessment was done on follow-up to monitor response.

Both groups demonstrated a statistically significant reduction in VAS scores from baseline to 12 weeks (p < 0.00001). At the 12-week time point, the Centchroman group showed significantly lower mean VAS scores compared to the Tamoxifen group (p = 0.016). Patient-reported satisfaction was higher in the Centchroman group (p = 0.131). Lump size reduction was observed in both Centchroman and Tamoxifen groups, but the changes were not statistically significant.

Centchroman is an effective and well-tolerated alternative to Tamoxifen for the management of mastalgia. It offers superior pain relief with better patient compliance and minimal side effects. However, tamoxifen or centrochroman did not appear to reduce the size of fibroadenomas. Centchroman may be considered a preferred first-line agent in the pharmacological treatment of mastalgia.